Specifically, 24 of 41 (59%) patients on DPP4 inhibitors progressed, while 73 of 120 (61%) patients on metformin had progression of prostate cancer (HR: 1.01; 95% CI: 0.64-1.61; p = 0.955) (Figure 2). Here, DPP4 is linked to prostate carcinoma.